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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows 
resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors targeting 
chromatin regulators as possible therapeutic agents in PDAC. We show that JQ1, an inhibitor of 
the bromodomain and extraterminal (BET) family of proteins, suppresses PDAC development in 
mice by inhibiting both MYC activity and inflammatory signals. The histone deacetylase (HDAC) 
inhibitor SAHA synergizes with JQ1 to augment cell death and more potently suppress advanced 
PDAC. Finally, using a CRISPR-Cas9–based method for gene editing directly in the mouse adult 
pancreas, we show that de-repression of p57 (also known as KIP2 or CDKN1C) upon combined 
BET and HDAC inhibition is required for the induction of combination therapy–induced cell death 
in PDAC. SAHA is approved for human use, and molecules similar to JQ1 are being tested in 
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clinical trials. Thus, these studies identify a promising epigenetic-based therapeutic strategy that 
may be rapidly implemented in fatal human tumors.
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of human pancreatic 
cancer, representing more than 95% of all cases. Despite recent advances in surgical 
techniques and adjuvant therapy, survival has changed little in the last 20 years, with a 5-
year survival rate hovering around 5%. Moreover, PDAC incidence has been increasing 
gradually to over 45,000 new cases in 2013 in the United States alone, where PDAC has 
been predicted to rapidly become the second most prevalent cancer killer1. Although some 
patients benefit from earlier diagnosis due to emerging imaging technologies (enabling the 
surgical removal of their tumors), even the most advanced chemotherapeutic regimens and 
virtually all targeted therapies have remained largely ineffective thus far (reviewed in refs. 
2–5).
The most frequent oncogenic event in human PDAC is mutation of KRAS (occurring in 
>95% of cases), which results in Ras activation. Activation of Ras signaling is thought to be 
both an initiating event and a key driver of PDAC6. Although inhibitors of enzymes in the 
Ras pathway exist, clinical trials using these inhibitors have not shown meaningful effects in 
PDAC, in part because of dose-limited toxicities and the emergence of resistant disease5,7. 
Other genetic alterations frequently found in human PDAC include inactivation of TP53, 
CDKN2A (also known as p16) or SMAD4 (refs. 8–11). The functional roles of these 
alterations have been validated in mouse models of PDAC11–16, and the resulting mice 
constitute preclinical models in which to investigate the mechanisms of PDAC development 
and identify and test new therapeutic approaches17.
Recent next-generation sequencing efforts have revealed frequent alterations in genes 
regulating chromatin remodeling and modification in human tumors9,18, which has led to the 
idea that the proteins encoded by these genes may be used as therapeutic targets in cancer, 
including in PDAC (reviewed in refs. 19,20). Here we investigate the effect of targeting in 
PDAC one such family of chromatin regulators, the BET (bromodomain and extra-terminal) 
family of proteins, which recognize acetylated lysines on histones through their 
bromodomains (BRD) and control the transcription of oncogenic drivers such as MYC21–23.
 RESULTS
 BET inhibition suppresses pancreatic tumorigenesis
First we examined the expression of BET family proteins in PDAC. We detected expression 
of BRD2, BRD3, and BRD4 in preneoplastic lesions and frank tumors in the 
Ptf1a+/Cre;Kras+/LSL-G12D mouse model of endogenous PDAC (hereafter referred to as 
Kras)12, in human tumors and in human cell lines (Fig. 1a,b and Supplementary Fig. 1a,b). 
On the basis of these observations, we examined the effects of treating primary mouse 
pancreatic acinar explants in culture with a small-molecule inhibitor of BET proteins ((+)-
JQ-1, hereafter JQ1; ref. 21). JQ1 treatment blocked acinar-to-ductal metaplasia (ADM), a 
key step in PDAC initiation24 observed in response to constant EGF stimulation, which 
mimics Ras activation (Fig. 1c). This repro-gramming block correlated with decreased c-
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MYC (hereafter MYC) levels in mouse acinar explants and the pancreas of Kras mice in 
vivo (Supplementary Fig. 2a,b). JQ1 treatment blocked pancreatic cell proliferation and the 
development of pancreatic intraepithelial neoplastic lesions (PanINs) in a mouse model of 
PDAC co-triggered by oncogenic K-Ras and caerulein-induced inflammation25 (Fig. 1d,e 
and Supplementary Fig. 2a–c). Immunoblot analysis showed decreased activation of the pro-
survival kinase AKT in pancreata from JQ1-treated mice; we also observed downregulation 
of the activity of inflammatory regulators such as STAT3 and IL6 in pancreata extracts upon 
JQ1 treatment, correlating with tumor inhibition (Fig. 1f and Supplementary Fig. 2b,c). 
These data suggest that JQ1 treatment may have chemopreventive effects in PDAC.
Treatment of human PDAC cell lines with JQ1 also led to lower MYC levels, induction of 
cell death, and decreased tumorigenic features in culture (Supplementary Fig. 1c – e; see 
also ref. 26). To further investigate the effects of JQ1 treatment on tumor maintenance in 
vivo, we used a highly aggressive mouse model of PDAC 
(Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP mice, hereafter referred to as Kras;p53), in which 
tumors develop within the first 6 weeks of life11. Short-term treatment (5 d) with JQ1 after 
tumors had formed resulted in reduced MYC expression and proliferation and increased 
apoptosis in this model (Supplementary Fig. 2d – g). This led us to investigate the long-term 
consequences of JQ1 treatment in established PDAC, both as a single agent and in 
combination with standard-of-care chemotherapy (gemcitabine), in a preclinical therapy trial 
setting7,27,28. Kras;p53 mutant mice were screened weekly for cancer development by 
MRI29 and were enrolled in the study upon development of a tumor volume of 
approximately 200–400 mm3 (Fig. 1g and Supplementary Fig. 3). As reported before in 
various mouse models29–31, gemcitabine monotherapy had no significant effect on tumor 
composition, tumor volume or mouse survival in this context (Fig. 1h – j), similar to what is 
seen in humans with PDAC. In contrast, JQ1 alone or in combination with gemcitabine led 
to a significant reduction in tumor volume, an increase in apoptosis and a decrease in 
proliferation, as well as decreased activity in pro-survival and pro-proliferative pathways 
(Supplementary Fig. 4). Inflammatory signals such as STAT3 and IL6 (Fig. 1j) and 
expression of the tumor-associated stroma marker smooth muscle actin and collagen 
(Supplementary Fig. 4) were also reduced upon JQ1 treatment. Notably, JQ1 treatment had 
only a modest effect on survival on its own and did not significantly synergize with 
chemotherapy under these conditions (Fig. 1h). Nevertheless, these experiments and recent 
reports32,33 support an acute therapeutic effect of JQ1 treatment in established PDAC tumors 
in vivo.
 BET inhibition blocks MYC and inflammation
To determine how JQ1 treatment blocks PDAC growth, we performed gene set enrichment 
analysis (GSEA) on gene expression profiles from JQ1-treated and control Kras;p53 mouse 
primary PDAC cells. This analysis identified a substantial downregulation of MYC targets in 
JQ1 treated cells (Fig. 2a). The MYC family of oncogenes has been implicated in the 
pathogenesis of most types of human tumors, including PDAC34, and we confirmed 
amplification and increased expression of MYC in human and mouse PDAC (Supplementary 
Fig. 5a–d). To investigate a role for MYC in PDAC development, we crossed Kras mice to 
Myc conditional mutant mice. Unlike Kras mice, which showed the expected formation of 
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preneoplastic lesions, mice with concomitant oncogenic Kras activation and Myc deletion at 
the time of cancer initiation showed attenuated development of preneoplastic lesions of both 
low and higher grades (Fig. 2b and Supplementary Fig. 5e,f). These data indicate that the 
inhibitory effects of JQ1 treatment on PDAC cells may in part be mediated by decreased 
MYC levels; however, BRD family proteins may also control the activity of other drivers of 
PDAC development.
Inflammatory mediators including STAT3 and IL6 drive pancreatic carcinogenesis35–38. 
Although MYC is known to promote tumorigenesis by controlling the tumor 
microenvironment39, we did not observe significant changes in pSTAT3 levels, inflammatory 
molecules or tumor stromal response in the absence of MYC (Supplementary Fig. 5e and 
data not shown). In contrast, we observed a marked reduction in IL6 and phospho-STAT3 
(pSTAT3) levels in Kras;p53 mutant mice treated with JQ1 (Fig. 1j and Supplementary Fig. 
4a). Furthermore, GSEA of JQ1-treated and control tumors revealed that signatures for 
growth factors, cytokines and immune-related processes were significantly decreased in 
JQ1-treated mice (Fig. 2c and Supplementary Fig. 5g–i). On the basis of these observations, 
we analyzed the serum of wild-type, control and JQ1-treated mice and found lower levels of 
inflammatory cytokines, including IL1a and IL6, in the serum of JQ1-treated animals (Fig. 
2d). IL1a and IL6 both promote pancreatic tumorigenesis35,36,40,41. Reduced levels of IL1A 
and IL6 mRNA were also noted in xenografts derived from humans with PDAC (patient-
derived xenografts, PDXs) treated with JQ1 (Fig. 2e). In addition, we observed a correlation 
between the expression levels of BET family members, MYC and a set of cytokines in 
human PDAC, further indicating that JQ1 treatment broadly affects inflammatory molecules 
(Supplementary Fig. 5j). Like JQ1 treatment, shRNA-mediated knockdown of BRD4 led to 
the downregulation of IL6 and pSTAT3 in human CFPac1 PDAC cells in culture, supporting 
a cell-intrinsic role for BET proteins in the regulation of the expression of inflammatory 
mediators in PDAC cells (Fig. 2f). Furthermore, chromatin immunoprecipitation assays in 
CFPac1 cells showed direct BRD4 association to the IL6 promoter, which was disrupted by 
JQ1 pretreatment (Fig. 2g,h). Finally, the protective effect of JQ1 treatment on tumor 
development could be reversed by exogenous injections of IL6, which led to reactivation of 
STAT3 phosphorylation and accelerated tumorigenesis (Fig. 2i,j and Supplementary Fig. 6). 
Collectively, these observations indicate that, in addition to MYC, inflammatory signals 
represent a second oncogenic driver that is downstream of BET family proteins in pancreatic 
tumorigenesis.
 Synergistic effects of JQ1 and the HDAC inhibitor SAHA
JQ1-treated mice eventually succumbed to PDAC (Fig. 1h). This led us to investigate 
additional agents that could be combined with JQ1 to more durably suppress PDAC. We 
selected eight drugs that target key Ras-dependent oncogenic or CDKN2A- or TP53-
dependent pathways or epigenetic regulators, and established a cell culture assay to screen 
for effective combination therapies. Inhibition of histone deacetylases (HDACs) with the 
small molecule SAHA (vorinostat) had a synergistic effect with BET protein inhibition in 
human CFPac1 cells, whereas other drug combinations were less effective (Fig. 3a and 
Supplementary Fig. 7). Co-treatment with JQ1 and SAHA led to a strong reduction in cell 
viability (Fig. 3b), which correlated with marked induction of apoptosis as measured by 
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annexin V staining, caspase 3 cleavage and reduction of expression of the anti-apoptotic 
proteins MCL1 and BCL-XL in several PDAC cell lines; in addition, JQ1 and SAHA 
treatment blocked the ability of human and mouse PDAC cells to form colonies at low 
density, a measure of decreased tumorigenic potential (Fig. 3b–e and Supplementary Fig. 8). 
JQ1 and SAHA also synergized to suppress the formation of MUC5AC-positive 
preneoplastic lesions in Kras mutant mice (Fig. 3f–h and Supplementary Fig. 9).
Based on these experiments on cancer initiation in vivo and tumor maintenance in vitro, we 
next evaluated the effect of combined JQ1+SAHA treatment on established PDAC in vivo. 
Kras;p53 mutant mice treated with JQ1+SAHA after development of a tumor volume of 
200–400 mm3 (Supplementary Fig. 3) showed a greatly reduced tumor volume, more so 
than Kras;p53 mutant mice treated with JQ1 alone, and had a significant improvement in 
overall survival(Fig. 4a–d). Of note, 4 of 10 mice treated in the combination arm had to be 
euthanized because of neurological symptoms due to Cre expression and tumor development 
in the brain42 (data not shown); this is usually not an issue in this mouse model because 
these mice normally die much faster from PDAC. Five of the remaining mice treated with 
the combination therapy developed bile drainage problems and were morbid due to jaundice 
rather than high tumor burden; one mouse died of unknown cause. Importantly, mice treated 
with JQ1+SAHA showed no evidence of tumor relapse, a sign of inherent or acquired 
resistance, such as is typically seen with other therapies, nor did they develop metastasis 
(data not shown). Residual small tumor clusters had a moderately differentiated histology, 
with some poorly or undifferentiated areas with strongly depleted stroma. The combination 
therapy led to a significant cell cycle inhibition (P < 0.05) and a significant increase in 
apoptotic cell death (P < 0.001) compared to JQ1 treatment alone (Supplementary Fig. 10).
A similar therapeutic effect was observed in a second highly aggressive mouse model of 
PDAC (Ptf1a+/Cre;Kras+/LSL-G12Dp16/p19loxP/loxP mutant mice, hereafter Kras;p16/19), in 
which tumors develop with a latency of 8 weeks43 (Supplementary Fig. 11a–d). Also, the 
combination therapy significantly inhibited the growth of two independent PDAC PDXs; 
this growth suppression was accompanied by reduced expression of MYC and pSTAT3 and 
reduced stromal response (Fig. 4e–g and Supplementary Fig. 11e–i).
Typically, increased cancer tumor burden is accompanied by the development of cachexia, 
but this weight loss was completely prevented by JQ1+SAHA treatment (Supplementary 
Fig. 12a,b). In addition, the histopathology and blood markers of the treated mice revealed 
no overt systemic toxicity due to the combination therapy (Supplementary Fig. 12c–h). 
Thus, the combined inhibition of BET family proteins and HDACs results in a potent and 
sustained antitumoral response.
To investigate whether the JQ1+SAHA combination therapy could be effective in other 
tumor types, we performed another set of experiments in lung cancer cells. As in PDAC, 
MYC and BET family proteins, including BRD4, were expressed in human lung 
adenocarcinoma (LAC) (Supplementary Fig. 13a–c). In a well-established mouse model of 
LAC based on activation of KrasG12D and loss of p53 (ref. 44), treatment with JQ1 and 
SAHA 70 d after cancer initiation, when mice have developed tumors, significantly 
increased the survival of the mutant mice (Fig. 5a–c), associated with lower MYC levels, 
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induction of cell death, and inhibition of proliferation (Supplementary Fig. 13c–g). 
Similarly, a lung cancer PDX showed significant growth inhibition upon JQ1 and SAHA 
treatment (Fig. 5d,e). Thus, the combination therapy seems to be effective against several 
types of transformed cells and tumor entities.
 In vivo gene-editing identifies the role of p57
To investigate the molecular basis for the strong induction of apoptotic cell death in tumors 
treated with JQ1 and SAHA, we analyzed gene expression profiles of primary cells from 
Kras;p53 mutant mice and biopsy tissue from human PDX treated with JQ1 or SAHA alone 
or in combination. GSEA of microarray data showed decreased expression of HDAC targets 
in JQ1+SAHA-treated primary cells from Kras;p53 mutant mice and in human PDX, as well 
as a general decrease in transcription, as would be expected (Supplementary Fig. 14a). 
Signatures for increased apoptosis and decreased mitosis were also highly enriched in 
JQ1+SAHA-treated human and mouse cells (Supplementary Fig. 14a). p57 (officially 
known as Cdkn1c) was the most synergistically de-repressed gene seen in an analysis of 
microarray data from JQ1+SAHA-treated mouse PDAC cells (Supplementary Fig. 14b). 
Defining synergy as an effect in excess over an additive effect of the two drugs, p57 mRNA 
levels were increased on average 3.28-fold over additivity. Interestingly, p57 transcription is 
repressed by MYC45. p57 transcription is also often silenced in PDAC by epigenetic 
mechanisms, and its expression can be restored by HDAC inhibition46. This increase in p57 
mRNA expression was validated at the protein level (Fig. 6a,b). Depletion of p57 using 
shRNA led to reduced levels of the apoptotic marker PARP in PDAC cells treated with 
JQ1+SAHA in culture (Fig. 6c), supporting a previously suggested role for p57 in promoting 
apoptosis47,48. We found increased acetylation of the p57 promoter by chromatin 
immunoprecipitation upon JQ1+SAHA treatment, correlating promoter acetylation with p57 
expression (Fig. 6d).
These experiments in primary cells from Kras;p53 mutant mice and in human PDX led us to 
investigate whether de-repression of p57 was in part responsible for the induction of cell 
death observed following inhibition of BET proteins and HDACs. To this end, we developed 
an approach of lentiviral injections in the pancreas of adult mice based on reagents recently 
developed to manipulate gene expression using the CRISPR-Cas9 system in the lung49. We 
cloned a single-guide RNA (sgRNA) targeting the mouse p57 gene (sgp57) into the pSECC 
lentiviral backbone and examined the consequences of deleting p57 in mouse PDAC tumors 
treated with JQ1+SAHA (Fig. 6e,f). Cohorts of Kras;p53 mutant mice were infected with 
pSECC-sgp57 or pSECC-sgControl (with a scrambled sgRNA) lentiviral vectors by direct 
injection into the mouse pancreas (Supplementary Fig. 15a). Although adult mice are 
refractory to Kras-induced pancreas tumorigenesis50,51, this block was overcome by 
inducing moderate pancreatitis with caerulein29 in this model (Fig. 6f). Successful 
recombination of the alleles flanked by loxP sites by the Cre recombinase was confirmed by 
the activation of a reporter allele (Fig. 6g and Supplementary Fig. 15a). Induction of Cas9-
mediated mutations in the p57 gene was verified using a Surveyor assay (Fig. 6h). Using this 
protocol, we observed that 3 of 8 mice developed tumors that lacked p57 expression, with 4 
additional mice showing partial loss (at least 70%), upon JQ1+SAHA treatment. All treated 
sgRNA-control animals expressed p57 under the same conditions (Fig. 6i and 
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Supplementary Fig. 15b,c). Notably, tumors with successful deletion of p57 showed a 
significant (P < 0.01) reduction in apoptosis when treated with JQ1+SAHA as compared to 
tumors treated with the combination therapy but infected with a control lentiviral vector 
(Fig. 6i), partially reversing the therapeutic effects of the combination therapy. Thus, p57 
may be one of the key mediators of the anticancer action of JQ1 and SAHA in PDAC cells.
 DISCUSSION
In this study we examined the possible use of small-molecule inhibitors of chromatin 
regulators in adenocarcinoma of the pancreas and the lung and found a potent synergistic 
tumor-suppressive effect between a specific inhibitor of the BET family proteins (JQ1, 
known as TEN-010 in clinical trials) and HDAC proteins (SAHA, also known as vorinostat, 
an FDA-approved drug). Although the mode of action of the two drugs is certainly 
multifaceted and certainly involves broad signaling and transcriptional changes in both 
tumor cells and the tumor stroma, we identified transcriptional induction of p57 as a key 
mediator of cell death upon JQ1+SAHA treatment in PDAC cells. We also noted faster 
migration for a pool of p57 protein upon treatment with JQ1+SAHA (see, for example, 
immunoblots in Fig. 6a,b), an effect which might be related to decreased phosphorylation of 
p57 by AKT, an event previously associated with higher p57 turnover rates52; this could 
provide an additional mechanism of p57 activation in this context. On the basis of these 
observations, we propose that MYC downregulation, reduced inflammation, and p57 
induction are some of the processes affected by JQ1 and SAHA in tumors (Fig. 6j), and we 
suggest that p57 status may be used as a possible biomarker for how tumors respond to the 
combined treatment.
Recently, a combination of a HDAC inhibitor and a demethylase inhibitor was found to 
synergistically inhibit a subtype of glioma53. Similarly, loss of the chromatin remodeler 
EZH2 has been shown to amplify Ras-driven transcription in glioma and melanoma and 
enhance the sensitivity of tumor cells to BRD4-based strategies54. Thus, combinations of 
small-molecule inhibitors targeting chromatin regulators may have limited toxicity and 
strong inhibitory effects in many cancer types. Future studies will investigate whether the 
marked response to JQ1 and SAHA is specific to PDAC and LAC, two cancers with 
important stromal and inflammatory components. In particular, the inhibitory effects of JQ1 
in a mouse model of Ras-driven lung adenocarcinoma are dependent on the tumor genotype, 
with loss of the Lkb1 tumor suppressor largely abolishing the anticancer effects of this 
drug55. Although we have performed our experiments with tumors bearing the most frequent 
genetic alterations in PDAC and LAC, it will be important in the future to investigate the 
effects of combined BET and HDAC inhibitors on subgroups of tumors with multiple 
genotypes. Nevertheless, our experiments identify a striking vulnerability to epigenetic-
based targeting approaches in pancreatic and lung cancers, two tumor types that are largely 
resistant to current therapeutic approaches, and will hopefully facilitate the rapid clinical 
evaluation of this new strategy.
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 ONLINE METHODS
 Ethics statement
Mice were maintained in accordance and compliance with policies approved by the Stanford 
University Administrative Panel on Laboratory Animal Care (Sage lab protocol #13565) and 
by the Institutional Animal Care and Use Committee at the Technical University of Munich.
 Mouse strains
Ptf1a+/Cre, Kras+/LSL-G12D, Trp53loxP/loxP, p16/p19loxP/loxP, MycloxP/loxP, R26LSL-CAG-
tdTomato and R26LSL-CAG-EYFP mice have been described before12,43,56–59. Mice were 
in a mixed C57BL/6;129/Sv background, and we systematically used littermates as controls 
in all the experiments (sex ratio per cohort balanced). All animals were numbered and 
experiments were conducted in a blinded fashion. After data collection, genotypes were 
revealed and animals assigned to groups for analysis. For treatment experiments mice were 
randomized. None of the mice with the appropriate genotype were excluded from this study. 
Histopathological analysis was conducted on de-identified slides by two pathologists (I.E. 
and B.S.). Animal experiments and care were in accordance with the guidelines of 
institutional authorities and approved by local authorities (see Ethics statement).
 Pancreatic cancer mouse models
 Pancreatitis-induced tumorigenesis—Acute pancreatitis was induced at 6 to 8 
weeks of age in Ptf1a+/Cre;Kras+/LSL-G12D (Kras) mice by administration of 8 hourly 
intraperitoneal (IP) injections of caerulein (100 µg/kg body weight) (Sigma-Aldrich) over 2 
consecutive days as described previously25,60. Mice were treated as indicated with JQ1 (25 
mg/kg twice daily, IP) and/or SAHA (25 mg/kg, once daily, Selleckchem) or vehicle 10% 
(2-hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich). The twice-daily injection regiment for 
JQ1 is based on in vivo drug stability data61. IL6 injections were performed intravenously 
(i.v.) (mouse recombinant IL6, 1 µg per mouse). Pancreatic lesions were analyzed 7 d after 
the last injection. In parallel animals were analyzed at day 0 to confirm the caerulein-
induced damage. None of the treatments affected the initial pancreatic injury (data not 
shown).
 Spontaneous model of pancreatic intraepithelial neoplasia (PanIN) 
development—PanIN progression was analyzed in Ptf1a+/Cre;Kras+/LSL-G12D (Kras) and 
Ptf1a+/Cre;Kras+/LSL-G12D; MycloxP/loxP (Kras;Myc) mice aged 6 months. Quantification of 
low- (PanIN1a and 1b) and high-grade (PanIN2 and 3) lesions was performed by a 
pathologist (B.S.). Histopathological analysis was conducted on de-identified slides based 
on the classification consensus62. Five images (×100) were taken in standardized positions 
(so as to cover the whole section) for each slide. PanINs were counted from 8 independent 
animals for each group. Error bars represent s.e.m.
To calculate the relative normal acini area, Kras and Kras;Myc tumor sections were stained 
for amylase. Positive regions on six random, non-overlapping, ×100 images were collected 
from 3 mice per genotype. For each image positive amylase area was normalized to total 
pancreas tissue area using ImageJ software. Error bars represent s.e.m.
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 Model of aggressive PDAC—long-term treatment—For survival studies, we used 
Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP (Kras;p53) mice, which develop aggressive, 
quickly fatal disease. Mice were followed for signs of disease progression. At the end of the 
experiment, tumors were processed for biochemical, histological and immunohistochemical 
analysis.
Mice were treated as indicated with JQ1 (25 mg/kg twice daily, IP) and/or SAHA (25 
mg/kg, once daily, Sigma-Aldrich) or vehicle 10% (2-hydroxypropyl)-β-cyclodextrin 
(Sigma-Aldrich). Gemcitabine (Sigma) was dissolved in saline and dosed at 100 mg/kg of 
gemcitabine on a Q3Dx4 schedule (every third day for 4 cycles) as previously 
described30,63.
 Model of aggressive PDAC—acute treatment—To study the short-term effects of 
JQ1 treatment on Kras;p53 mutant tumors, 35d old animals with fully developed PDAC 
were treated with JQ1 (25 mg/kg twice daily, IP) over 5 d.
 CRISPR-Cas9–mediated direct genome editing in the mouse pancreas
 Plasmid and lentivirus preparation—The U6-sgRNA-EFS-Cas9-2A–Cre (pSECC) 
lentiviral vector was described previously49. For sgRNA cloning, the pSECC vector was 
digested with BsmBI and ligated with annealed oligos with complementary BsmBI 
fragments. Specific sgRNAs were designed using CRISPR Design64,65 to avoid potential 
off-target sites. A Cdkn1c specific guide RNA (PAM sequence underlined) pre-validated in 
vitro was used: GCGC TGCTACGCGCTATCACTGG. Lentivirus was produced and titered 
as described previously66. Briefly, the pSECC vector was co-transfected with packaging 
vectors into 293T cells using polyethylenimine (PEI) transfection. The supernatant was 
collected at 48, 72 and 96 h. Concentrated virus was recovered by ultracentrifugation at 
25,000 r.p.m. for 120 min and re-suspended in 25 µl PBS with 1% (vol/vol) Matrigel (BD 
Matrigel Growth Factor Reduced, BD Biosciences).
 Lentiviral injections to the pancreas—pSECC allows expression of target sgRNA 
and the Cas9 nuclease with the Cre recombinase. This results in simultaneous genome 
editing and Cre-mediated activation of KrasG12D and ablation of Trp53 in infected mouse 
pancreata. This model enables rapid, flexible, and scalable investigation of gene function in 
vivo. Cohorts of Kras+/LSL-G12D;Trp53loxP/loxP mice were infected with pSECC-sgp57 or 
pSECC-sgControl lentiviral vectors by direct injection into the pancreas. The recipient mice 
were anesthetized with isoflurane. Anesthesia depth was assessed based on withdrawal 
reflex immediately before making an incision and monitored continuously during the 
surgery. The hair on the ventral surface of the mouse was shaved and the incision site was 
disinfected with iodophors (Betadine scrub). A disposable surgical drape (precut and 
sterilized) was placed, and mice were subjected to laparotomy. The incision size was ~1 cm 
long depending on the size of the individual animal. The splenic part of the pancreas was 
exposed and the viral solution was slowly injected into the pancreas parenchyma using a 30-
gauge needle over 30 s to avoid backward flow. The addition of Matrigel to the injected 
virus solutions resulted in immediate increased viscosity of the injected fluid and mitigated 
leakage to prevent transduction outside of the pancreatic tissue (see Supplementary Fig. 15). 
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This injection procedure mimics the previously described protocols for xenograft cell 
implantation67. The successful introduction of lentiviral particles into the pancreas 
parenchyma does not lead to significant side effects, such as pancreatitis, as previously 
described for intraductal viral administration68. Risk of vascular damage can be minimized 
by passing the needle parallel to any visible vessels, along the length of the pancreas. 
Finally, the abdominal muscle layer was closed with interrupted suture and the overlying 
skin was closed using Monocryl sutures (Ethicon).
 Pancreatitis induction and treatment—Adult mice normally become refractory to 
KrasG12D-induced pancreas tumorigenesis, but if these mice are challenged with a mild form 
of chronic pancreatitis, they develop the full spectrum of PanINs and invasive PDAC50. 
Thus, mice were “primed” with 250 µg/kg caerulein twice daily for 5 consecutive days29 
after lentiviral injection. All successfully transduced animals developed pancreatic tumors. 
We did not observe sarcoma development in the pancreas, however, in one case we noticed a 
mesenteric tumor and in few cases neoplastic growth in the peritoneal cavity around the area 
where the injection was performed.
 Analysis of p57 positive areas—Tumor sections were immunostained for p57. For 
each tumor, the p57-positive area was normalized to the total tumor area using ImageJ 
software. The distribution of p57 staining status in all infected animals was divided in three 
groups: negative (<30% of the tumor area stained positive for p57), mixed (30–70% of 
tumor area stained positive for p57) and positive tumors (70–100% of the tumor area stained 
positive for p57).
 Confirmation of Cas9 targeted loci mutation by T7E1 assay (Surveyor 
assay)—Mutation detection using the T7 (Surveyor) nuclease was performed as previously 
described69. Briefly, PCR products spanning the potential repair/damage sites were 
amplified and a mixture of 9 µl of PCR products and 1 µl of NEB buffer 2 was melted and 
re-annealed in a thermal cycler under the following conditions: 95 °C for 10 min, 95 °C to 
85 °C at 2 °C/s, 85 °C for 1 min, 85 °C to 25 °C at 0.1 °C/s, 25 °C for 1 min and 4 °C for an 
indefinite period. Exactly 6 µl of the re-annealed mixture was treated with 0.5 µl of T7 
endonuclease I (5 units) by addition of 0.4 µl of NEB buffer 2 and 3.1 µl of ddH2O at 37 °C 
for 20 min. Analysis by 2% agarose-gel electrophoresis followed. The gel was stained with 1 
µg/ml ethidium bromide in Tris-acetate-EDTA buffer for 5 min and then imaged with a gel-
imaging system (Bio-Rad).
 In vivo imaging and tumor volume measurements
As a model of locally advanced PDAC for imaging-guided tumor response evaluation, we 
used Kras;p53 mutant mice. MR imaging experiments were initiated at an age of 
approximately 30 d and were performed weekly. Before imaging, mice were anesthetized by 
continuous gaseous infusion of 2% isoflurane (Abbott) for at least 10 min using a veterinary 
anesthesia System (Vetland Medical). During imaging, the dose was kept at 2% isoflurane, 
animal temperature was maintained and continuously monitored and eyes were protected 
with an eye ointment. Tumor growth kinetics changes were followed with T2 weighted 
imaging protocol using microscopy surface coil inside a Philips 1.5T or 3.0T clinical 
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scanner. An axial multi-slice T2-weighted (T2w) TSE sequence (resolution 0.3 × 0.3 × 0.7 
mm3, minimum 30 slices, TE = 90 ms, TR>3 s) was applied for tumor detection. Solid 
tumor volumes were calculated using in house optimized ImageJ based software that 
differentiates between solid and cystic parts of the tumor (Supplementary Fig. 3a). By 
analyzing multiple mice at sequential time points, we found PDAC development occurring at 
4–6 weeks in Kras;p53 mutant mice with 100% penetrance. On average, tumors of animals 
at age 41 d met inclusion criteria of 200–400 mm3 of tumor mass (Supplementary Fig. 3b).
 Preparation of pancreatic epithelial explants culture
Pancreatic epithelial explants from 4- to 6-week old wild-type mice were established by 
modification of previously published protocols60. In brief, the whole pancreas was harvested 
and treated twice with 1.2 mg/ml collagenase-VIII (Sigma-Aldrich). Following multiple 
wash steps with McCoy’s medium containing soybean trypsin inhibitor (SBTI, 0.2 mg/ml), 
digested samples were filtered through a 100 µm filter, resuspended in culture medium 
(Waymouth’s MB 752/1 supplemented with 0.1% BSA, 0.2 mg/ml SBTI; 50 µg/ml bovine 
pituitary extract, 10 µg/ml Insulin, 5 µg/ml transferrin, 6.7 ng/ml selenium in 30% FCS) and 
allowed to recover for 1h at 37 °C. Thereafter, cells were pelleted and resuspended in culture 
medium supplemented with penicillin G (1000 U/ml), streptomycin (100 µg/ml), 
amphotericin B, 0.1% FCS, and an equal volume of rat tail collagen and immediately plated 
on plates pre-coated with 2.5 mg/ml of rat tail collagen type I. In stimulation experiments, 
recombinant human EGF (rhEGF, Invitrogen) was added at final concentration of 25 ng/ml. 
Cells were treated with JQ1 at a concentration of 250 nM. For quantification, acinar explants 
were seeded in triplicates. Cell clusters were counted from at least 3 optical fields/well and 
reported as a percentage of acinar clusters and duct-like spheres. The quantification was 
performed in two independent experiments; the number of mice is reported in the main text.
 Lung adenocarcinoma (LAC) mouse model
Kras+/LSL-G12D;Trp53loxP/loxP (Kras;p53) mice were treated with 5 × 106 pfu of adenovirus 
expressing Cre (University of Iowa adenovirus core) by intratracheal infection as previously 
described70.
 Patient fresh PDAC biopsies and patient-derived xenograft (PDX) tumors
Tissue samples were collected from patients following pancreatic resection for PDAC at the 
Technische Universität München and Ruhr-University Bochum. All patients were informed 
and written consent was obtained. The tissue collection was performed according to a 
protocol approved by the Ethics Committee of the Ruhr-University Bochum (permission no. 
3534-09 and 3841-10) and the Ethics Committee of the Technische Universität München 
(Project number: 5510/12). The lung adenocarcinoma (LAC) patient-derived xenograft (Fig. 
5) was obtained from the Stanford University medical center following IRB approval. The 
LAC sample bears a KrasG12V mutation and is wild-type for EGFR and ALK. PDAC 
samples have KrasG12V mutations and did not express CDKN2A transcripts.
The fresh tumor samples were initially grown directly in the mouse as a tissue fragment. 
Then tumors were minced using a razor blade and digested in collagenase/dispase digestion 
buffer (Roche) for 1 h at 37 °C. Cells were passed through 10 µm and 40 µm cell strainers 
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and centrifuged for 1,200 rpm for 8 min. Cells were incubated in RBC lysis buffer for 2 min 
and then resuspended in 6 ml of media and spun through 0.5 ml of serum layered on the 
bottom of the tube to remove cellular debris. Cells were depleted of lineage-positive cells 
using biotin conjugated anti-mouse CD45, CD31 and Ter119 (eBiosciences) and depleted on 
a MACS LS column (Miltenyi Biotec) using anti-biotin microbeads per the manufacturer’s 
directions. After this procedure, single cells (500,000) were mixed with Matrigel (BD 
Biosciences) and injected into 6- to 8-week-old female NOD/scid mouse flank. Tumor 
volume was measured at the times indicated and calculated using the ellipsoid formula 
(length × width2).
Xenograft tumors (Supplementary Fig. 11e–i) from early passage human PDACs were 
grown in female NMRI-nu/nu mice treated with vehicle or JQ1 and SAHA (JQ1 50 mg/kg, 
SAHA 25 mg/kg once daily) for 21 d.
 Serum analysis and cytokine ELISA
Cytokine concentrations in serum were measured using the Mouse Inflammatory Cytokines 
& Chemokines Multi-Analyte ELISArray Kit (Qiagen) according to the manufacturer’s 
specifications. Data are presented as relative to the WT and treatment controls. Sera were 
collected from the blood samples of individual mice at the end of the experiment under 
terminal anesthesia following a protocol for cardiac puncture. Serum samples were separated 
from blood within 1 h following blood collection by centrifugation at 500g for 10 min. 
Separated samples were aliquotted and stored at −80 °C for subsequent testing. Media 
concentration of IL-6 was measured using human-specific ELISA kits (Pierce) according to 
the manufacturer’s protocols.
Aspartate transaminase (AST), alanine transaminase (ALT) and blood urea nitrogen (BUN) 
levels were measured in serum prepared as indicated above at the Animal Diagnostic 
Laboratory at Stanford Veterinary Service Center.
 Histology and immunohistochemistry
Tissue specimens were fixed in 4% buffered formalin for 24 h and stored in 70% ethanol 
until paraffin embedding. 3-µm sections were stained with hematoxylin and eosin (HE), 
Sirius Red or used for immunohistochemical studies.
Immunohistochemistry was performed on formalin-fixed, paraffin embedded mouse and 
human tissue sections using a biotin-avidin method as described before71. The following 
antibodies were used (at the indicated dilutions): Albumin (#PA5–27707, Thermo Scientific, 
1:1,000), αSMA (#5694, Abcam, 1:500), β-catenin (#610154, BD Bioscience, 1:1 000), 
BRD4 (#13440, Cell Signaling, 1:200), CK19 (#TromaIII, Developmental Studies 
Hybridoma Bank, 1:500), cleaved caspase 3 (#9664, Cell Signaling, 1:200), CD45 
(#ab10558, Abcam, 1:100), CD31 (#550274, BD Pharmingen, 1:100), F4/80 (#48000, 
Invitrogen, 1:500), IAP (#ab137879, Abcam, 1:250), Ki67 (#550609, BD Bioscience, 
1:1,000), MUC5AC (#145P1, NeoMarkers, 1:500), MUC2 (#sc-15335, Santa Cruz 
Biotechnology, 1:100), MYC (#39688, Abcam, 1:250), p57/Kip2 (#ab75974, Abcam, 
1:200), pAKT (#2965, Cell Signaling, 1:100), pERK1/2 (#4370, Cell Signaling, 1:500), 
pSTAT3 (#9145, Cell Signaling, 1:500), PDX1 (a generous gift of Dr. C. V. Wright, 
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1:10,000), SOX9 (#AB5535, EMD Millipore, 1:250). Sections were developed with DAB 
and counterstained with hematoxylin. Pictures were taken using a Zeiss microscope 
equipped with the Axiovision software. Analysis of the tumor area and IHC analysis was 
done using ImageJ software by measuring pixel units.
 Cell culture, reagents and transfections
Authenticated cancer cells (of various genotypes): CFPac1 (KrasG12V;p53C242R), Panc1 
(KrasG12D;p53R273H), CaPan1 (KrasG12V;p53A159V;Smad4S343*), CaPan2 
(KrasG12D;p53T125C), HPFAII (KrasG12D;p53T151S;Cdkn2aR29_A34del), Colo357 
(KrasG12V;Smad4mut), Panc89 (p53mut;Cdkn2amut), PaTu8902 (KrasG12V;p53C176S), 
SW1990 (KrasG12D;p53P191del), AsPC1 (KrasG12D;p53C135fs*35:Smad4R100T), MiaPaCa2 
(KrasG12C;p53R248W), YPAC (KrasG12V;p53H179R;Smad4R515fs*22), BxPC1 (p53Y220C), 
293T were obtained from the American Type Culture Collection and DanG 
(KrasG12V;p53993+16del.38;Smad4mut) cells were obtained from CLS Cell Lines Service 
GmbH and cultured in RPMI Medium supplemented with 10% FCS (Life Technologies), 
100 units/ml penicillin/streptomycin and glutamine (Life Technologies). Primary mouse 
pancreatic cancer lines were obtained from Kras;p53 mouse PDAC. Cells were grown in 
Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% FCS 
(Life Technologies), 100 units/ml penicillin/streptomycin and glutamine (Life 
Technologies). All cells were cultured at 37 °C in a humidified incubator with 5% CO2. All 
cell lines were routinely evaluated for mycoplasma contamination.
 Lentiviral shRNA constructs
shRNA sequences targeting MYC, BRD4 and p57, published previously72, were cloned in a 
pLKO vector carrying a puromycin resistance gene. Lentiviruses were generated in 293T 
cells using second-generation packaging vectors. Target cells were infected and selected 
using puromycin selection (2 µg/ml puromycin for 1 week, Invitrogen).
 Cell assays
 Cell viability—Cells were seeded in 96-well plates at 2,000 cells per well (optimal 
density for growth) in a total volume of 100 µl media containing 2% FBS. Serially diluted 
compounds in 100 µl media were added to the cells 12 h later. After 72 h incubation, cell 
viability was assessed by an MTT assay (Roche) according to the manufacturer’s 
instructions.
 Invasion assays—Twenty-four hours after 250 nM JQ1 treatment, 100,000 of the 
indicated cells were seeded in a Transwell chamber pre-coated with Matrigel (BD 
Biosciences). Medium containing 10% FBS in the lower chamber served as chemoattractant. 
JQ1 was added to both upper and lower chambers. After 48 h, the non-invading cells and 
extracellular matrix were gently removed with a cotton swab and invasive cells located on 
the lower side of the chamber were stained with crystal violet and photographed. For 
colorimetric assays, the stained wells were treated with 500 µl 10% acetic acid and the 
absorbance was measured at 560 nm using a spectrophotometer.
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 Colony-formation assay—For long-term colony-formation assay, 10,000–50,000 cells 
per well were seeded in 6-well plates and treated with JQ1 or DMSO. After 12 d, cells were 
fixed with methanol, stained with crystal violet, photographed and quantified.
 Senescence associated-X-gal staining—Staining was carried out as described 
previously73. Briefly, cells were grown subconfluently on cell culture chamber slides, treated 
with indicated concentration of JQ1 for 48 h and then incubated with fixative 
(glutaraldehyde) followed by the chromogenic SA-β-galactosidase substrate X-gal in a 
buffer at pH 6.0. After a blue color developed (12 h), the cells were washed with phosphate-
buffered saline (PBS) and viewed by bright field or phase contrast microscopy.
 Annexin V apoptosis staining—Staining was performed according to the 
manufacturer’s protocol (BD, APC annexin V). Cells were grown in 10 cm plates and 
treated with varying concentrations of JQ1. Annexin V was quantified in various cells 
selectively for an early apoptotic cells (annexin V+, DAPI−), excluding accumulated dead 
cells (annexin V+, DAPI+). All analyses were performed using Flowing Software 2.1 and 
independently repeated.
 Synergy screening and calculations
Cells were seeded in 96-well plates at 2,000 cells per well (optimal density for growth) in a 
total volume of 100 µl media containing 2% FBS. The following day, cells were treated in 
duplicate with single agents and their fixed-ratio combination for 72 h over a 5-point, 32-
fold concentration range, which was centered on the single-agent concentrations that 
inhibited viability by 50% (IC50). Cell viability was measured by MTT assay (Roche) 
according to the manufacturer’s instructions.
Combination index (CI) scores were calculated as previously described74 using CalcuSyn 
software (Biosoft)75. This software uses the Chou-Talalay combination index method, which 
is based on the median-effect equation, itself a derivation from the mass-action law. For this 
analysis, Drug1 was combined with Drug2 at a constant ratio determined by IC50Drug1/
IC50Drug2. We entered the resulting proliferation data, along with the data obtained from 
single drug treatments, into CalcuSyn to determine a combination index value (CI) for each 
combination point, which quantitatively defines additivity (1 < CI > 1.5), synergy (CI < 1), 
and antagonism (CI > 1.5). The resulting values were used to construct a plot of CI values 
over a range of fractions affected. The drug synergy screen was performed in CFPac1 cells 
using 9 targeted inhibitors (range of concentrations tested): BRDi (JQ1, 125–4,000 nM), 
HDACi (SAHA, 125–4,000 nM), MEKi (CI1040, 31.25–1,000 nM), PI3Ki (GDC0941, 
31.25–1,000 nM), IGF1Ri (OSI–906, 31.25–1,000 nM), EGFRi (erlotinib, 12.5–400 nM), 
STAT3i (Stattic, 250–8,000 nM), SRCi (fasatinib 12.5–400 nM) and CDK4i (PD0332991, 
250–8,000 nM).
 Cell extracts and immunoblot analysis
For total cell extracts, cells were lysed in RIPA buffer (10 mM Tris-HCl pH 8, 150 mM 
NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton, 0.1% SDS, 1 mM PMSF, protease inhibitors 
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(Roche) and a phosphatase inhibitor cocktail (Sigma-Aldrich)) for 15 min. Protein 
concentration was determined by the BCA assay (Pierce).
Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membrane and analyzed 
by immunoblot. Antibodies used were as follows (with the indicated dilutions): pAKT 
(#2965, 1:1,000), AKT (#4685, 1:1,000), pERK1/2 (#4370, 1:3,000), ERK1/2 (#4695, 
1:3,000), pSTAT3 (#9145, 1:1,000), STAT3 (#12640, 1:1,000), BRD4 (#13440, 1:1,000), 
BRD2 (#5848, 1:1,000), BCL-XL (#2764, 1:1,000), cleaved caspase 3 (#9664, 1:1,000), 
cleaved PARP (#9546, 1:1,000, human specific; 9548, 1:1,000, mouse specific), IL6 
(#12912, 1:1,000) MYC (#9402, 1:1,000) and HDAC1 (#2062, 1:1,000) were purchased 
from Cell Signaling Technology; cyclinD1 (#16663, 1:1,000) and p57Kip2 (#ab75974, 
1:500) from Abcam; BRD3 (#a302–367, 1:500) from Bethyl, beta-tubulin (#05–661, 
1:10,000) from Millipore, MCL1 (#sc-819, 1:1,000) from Santa Cruz Biotechnology, and 
beta-actin (#A5316, 1:5,000) and GAPDH (#G8795, 1:5,000) from Sigma-Aldrich.
 qRT-PCR
RNA was isolated using the Qiagen RNeasy Isolation Kit followed by cDNA synthesis 
(SuperScript II, Invitrogen). Real-Time PCR was performed with 800 nM primers diluted in 
a final volume of 20 µl in SYBR Green Reaction Mix (Applied Biosystems). RT-PCRs were 
performed as follows: 95 °C for 10 min, 35 cycles of 95 °C for 15 s and 60 °C for 1 min. 
qRT-PCR data are representative of 4 independent mouse tumor biopsy isolations per 
treatment. All samples were analyzed in triplicate. Gapdh expression was used for 
normalization. The following primers were used: hIL6 For 5′ 
GGTACATCCTCGACGGCATCT; hIL6 Rev 5′ GTGCCTCTTTGCTGCTTTCAC; hIL1A 
For 5′ TGTATGTGACTGCC CAAGATGAAG; hIL1A Rev 5′ 
AGAGGAGGTTGGTCTCACTACC; hGAPDH For 5′ CAACGGATTTGGTCGTATTGG; 
hGAPDH; Rev 5′ TGATGGCAACA ATATCCACTTTACC; mIl6 For 5′ 
CTCTGGGAAATCGTGGAAAT; mIl6 Rev 5′ CCAGTTTGGTAGCATCCATC; mMyc For 
5′AGCTGTTTGAAGGCTGG ATT; mMyc Rev 5′ AATAGGGCTGTACGGAGTCG; 
mGapdh For 5′ AAGG TCATCCCAGAGCTGAA mGapdh Rev 5′ 
CTGCTTCACCACCTTCTTGA.
 Quantitative chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described76. Briefly, to crosslink DNA with chromatin, 
CFPac1 (1 × 107 cells) were incubated for 15 min in 1% formaldehyde at room temperature. 
Fixation was quenched by the addition of glycine to a final concentration of 0.125 M for 5 
min at room temperature. Fixed cells were washed in ice-cold PBS, pelleted, and frozen at 
−80 °C or resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, 
with protease inhibitor), and the DNA with chromatin was broken into 200- to 1,000-bp 
fragments by sonication using a Virsonic probe sonicator at setting 2 at 20% output power 
for 8 cycles of 15 s. The chromatin was precleared with protein A Sepharose beads (GE 
Healthcare) before being diluted and bound by 4 µg of the primary antibody overnight at 
4 °C. Following antibodies were used for immunoprecipitation: BRD4 clone E2A7X 
(#13440, Cell Signaling), H3Ac (#06–599, Millipore) or IgG as background control. After 
precipitation, the DNA was purified by spin columns (Qiagen). Quantitative PCR was 
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performed using a real-time thermal cycler (Bio-Rad). Reactions were set up in triplicate for 
each sample with 800 nM primers diluted in a final volume of 20 µl in SYBR Green 
Reaction Mix (Applied Biosystems). qPCRs were performed as follows: 95 °C for 10 min, 
35 cycles of 95 °C for 15 s and 60 °C for 1 min. For BRD4 ChIP, six sets of primers located 
from −1141 to +118 bp relative to the IL-6 transcriptional start site (+1) were used: Region 
A: −1141 to −1061; IL6-A For 5′ GGGCTTCTGAACCAGCTTGA, IL6-A Rev 5′ 
CAGGCACGGCTCTAGGCTC. Region B: −981 to −900; IL6-B For 5′ 
AAGATGCCACAAGGTCCTCCT; IL6-B Rev 5′ CCACTTGGTTCAGGGC AGA. Region 
C: −720 to −621; IL6-C For 5′ CAGCAGCCAACCTCCTCTAAGT, IL6-C Rev 5′ 
CAAGGCGTCTCCAGGTGG. Region D: −600 to −500; IL6-D For 5′ 
AGGATGGCCAGGCAGTTCTA, IL6-D Rev 5′ AAGCCTGGGATTATGA AGAAGGTA. 
Region E: −327 to −225; IL6-E For 5′ TGCATGACTT CAGCTTTACTC, IL6-E Rev 5′ 
GCAGAACCACTCTTCCTTTAC. Region F: +18 to +118; IL6-F For 5′ 
ACCGGGAACGAAAGAGAAGC, IL6-F Rev 5′ CTGGCAGTTCCAGGGCTAAG.
H3Ac27 ChIP was performed across the CDKN1C transcription start site from −72 to +89: 
p57 For 5′ GTATAAAGGGGGCGCAGGCGGGCT, p57 Rev 
5’TGGTGGACTCTTCTGCGTCGGGTTC.
Calculation of average cycle threshold (Ct) and s.d. for triplicate reactions was performed, 
and each DNA fraction was normalized to the input to account for chromatin sample 
preparation differences: ΔCtnorm ChIP = CtChIP – Ctinput – log2(dilution), where “dilution” is 
input dilution factor = 100. Normalized background was then subtracted using the following 
equation: ΔΔCt = ΔCtnorm ChIP – ΔCtnorm IgG. The s.d. was calculated using propagation of 
error:
Calculation of relative quantity of amplified sequence (fold enrichment) was carried out 
according to the following equation:
Q = 2−ΔΔCt and calculation of error for relative quantity: Qerror ± = Q 
± 2−(ΔΔCt ± SDΔΔCt).
 Meta-analysis of public PDAC data sets
We downloaded raw data for 7 publicly available PDAC gene expression studies from the 
NCBI GEO and EBI ArrayExpress. After re-annotating the probes, each data set was 
separately normalized using GCRMA. We applied two meta-analysis approaches to the 
normalized data77. Briefly, the first approach combines effect sizes from each data set into a 
meta-effect size to estimate the amount of change in expression across all data sets. For each 
gene in each data set, an effect size was computed using Hedges’ adjusted g. If multiple 
probes mapped to a gene, the effect size for each gene was summarized using the fixed effect 
inverse-variance model. We combined study-specific effect sizes to obtain the pooled effect 
size and its standard error using the random effects inverse-variance technique. We 
computed z-statistics as a ratio of the pooled effect size to its standard error for each gene, 
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and compared the result to a standard normal distribution to obtain a nominal P-value. P-
values were corrected for multiple hypotheses testing using FDR78. We used a second non-
parametric meta-analysis that combines P-values from individual experiments to identify 
genes with a large effect size in all datasets. Briefly, we calculated a t-statistic for each gene 
in each study. After computing one-tail P-values for each gene, they were corrected for 
multiple hypotheses using FDR. Next, we used Fisher’s sum of logs method, which sums the 
logarithm of corrected P-values across all data sets for each gene, and compares the sum 
against a chi-square distribution with 2k degrees of freedom, where k is the number of data 
sets used in the analysis.
 Gene Chip analysis and GSEA
For expression profiling, primary mouse PDAC cells treated with vehicle, JQ1 (1 µM), 
SAHA (2 µM) or JQ1+SAHA (1 µM/2 µM) for 6 h and JQ1+SAHA-treated and control 
tissue samples of the patient-derived xenografts (Supplementary Fig. 11e–i) were used.
Total RNA was isolated using the Qiagen RNeasy Isolation Kit. RNA quality was assessed 
on an Agilent 2100 Bioanalyser, RNA 6000 Pico Series II Chips (Agilent). A total of 6 µg of 
labeled RNA was hybridized to mouse (Mouse Genome 430 p.m. 16-Array Plate; 
Affymetrix) or human (Agilent Human Genome Oligo Microarrays) expression gene chip 
arrays according to the manufacturer’s protocols. The microarray protocols and data 
reported in this article have been deposited in NCBI’s Gene Expression Omnibus (GEO) 
database, accession numbers GSE 64836 and 64837. GSEA software was provided by the 
Broad Institute of the Massachusetts Institute of Technology and Harvard University (http://
www.broad.mit.edu/gsea/)79. For both gene sets, we used the default parameters of the 
GSEA software package; the genes set permutation was used. In brief, the normalized 
enrichment score (NES) provides “the degree to which a gene set is overrepresented at the 
top or bottom of a ranked list of genes.” The false discovery rate q-value (FDR) is “the 
estimated probability that a gene set with a given NES represents a false positive finding”. In 
general, given the lack of coherence in most expression data sets and the relatively small 
number of gene sets being analyzed, an FDR cutoff of 25% was considered appropriate.
 Gene expression correlation
Heatmaps represent the Pearson correlation between expression of the noted genes in 
GSE15471 human pancreatic cancer expression data set. Heatmaps were created in R using 
the “pheatmap” package.
 Statistics
Kaplan-Meier survival curves were calculated using the survival time for each mouse from 
all littermate groups. The log-rank test was used to test for significant differences between 
the groups. For image quantification and gene expression analysis, statistical significance 
was assayed by Student’s t-test with Prism GraphPad software (two-tailed unpaired and 
paired t-test depending on the experiment—variance was first systematically examined using 
an F-test). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns: not significant. Data are represented 
as mean ± s.e.m.
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 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
BET protein inhibition suppresses PDAC growth and improves survival in a PDAC mouse 
model. (a) Immunoblot analysis with the indicated antibodies on tumor lysates from wild-
type pancreas and from pancreas of Ptf1a+/Cre;Kras+/LSL-G12D (Kras) mutant mice at 4.5 and 
9 months of age (two biological replicates). β-tubulin serves as a loading control. (b) 
Immunohistochemical analysis of BRD4 expression (brown signal with hematoxylin purple 
counterstain) on sections from mouse and human PDAC tumors (representative of 12 
independent samples). Scale bars, 100 µm, insets 50 µm. (c) Representative images of wild-
type mouse acinar clusters (asterisks) undergoing acinar-to-ductal metaplasia (ADM) 
forming ducts (arrowheads) ex vivo in response to co-culture with EGF or vehicle control 
for 3 d. Scale bars, 100 µm. Quantification of acinar and ductal clusters on day 3 of culture 
(right panel), (four independent biological replicates with three technical replicates each). 
**P < 0.01; n.s., not significant (two-tailed unpaired Student’s t-test). Data are represented 
as mean ± s.e.m. (d) Schematic of the caerulein pancreatitis–induced precancerous (PanINs) 
lesion formation protocol used for JQ1 treatment of Kras mice. (e) Representative examples 
of six pancreata images (scale bars, 1 cm) and hematoxylin and eosin (HE) staining (scale 
bars, 100 µm) (left panel). Quantification of MUC5AC-positive lesions in caerulein-treated 
pancreata from Kras control (vehicle) (n = 6) and JQ1 treated (n = 6) mice (right panel). 
***P < 0.001 (two-tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m. 
(f) Immunoblots with the indicated antibodies of pancreatic tissue lysates from wild-type 
(WT) and Kras mutant control (vehicle) and JQ1-treated mice. (g) Treatment schedule for 
administration of JQ1, gemcitabine (Gem) or vehicle. Ptf1a+/Cre; 
Kras+/LSL-G12D;Trp53loxP/loxP (Kras;p53) mutant mice undergoing gemcitabine 
monotherapy also received vehicle. (h) Kaplan-Meier survival curves of Kras;p53 mutant 
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mice from enrollment time in control (vehicle) (n = 9, median survival = 15 d), gemcitabine 
(Gem; n = 7, median survival = 18 d), JQ1 (n = 9 median survival = 24 d) and combined 
Gem + JQ1 (n = 8, median survival = 27 d) treatment groups. *P < 0.05; ***P < 0.001; n.s., 
not significant by log-rank test for significance. (i) Left, representative MRI scan at endpoint 
measurement of tumor size in Kras;p53 mice. Scale bars, 1 cm. Red dotted lines indicate 
tumor area. Right, tumor volume quantification at endpoint based on MRI scan (detailed 
procedure description in Online Methods and Supplementary Fig. 3) of mice in the treatment 
groups: control, n = 9; Gem, n = 5; JQ1, n = 6; Gem + JQ1, n = 6. *P < 0.05; ***P < 0.001; 
n.s., not significant (two-tailed unpaired Student’s t-test). Data are represented as mean ± 
s.e.m. (j) Immunoblot analysis of MYC, phospho-STAT3 (pSTAT3), phospho-AKT (pAKT) 
and IL6 levels in tumor biopsies collected from control and JQ1-treated Kras;p53 mutant 
mice (multiple independent mouse tumors were obtained and analyzed, two independent and 
representative samples are shown).
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Figure 2. 
MYC and inflammation are key tumorigenic drivers of PDAC that are inhibited by JQ1 
treatment and BET protein inhibition. (a) Gene set enrichment analysis (GSEA) in JQ1-
treated compared to vehicle-treated Kras;p53 mouse primary PDAC cells. (b) Quantification 
of spontaneous PanIN lesions formed in 6-month-old Kras (n = 8) and Kras;Myc (n = 8) 
mutant mice. The grade of lesions is indicated. **P < 0.01; ***P < 0.001 (two-tailed 
unpaired Student’s t-test). Data are represented as mean ± s.e.m. (c) GSEA from data sets 
comparing vehicle- to JQ1-treated Kras;p53 mouse primary PDAC cells (see also 
Supplementary Fig. 5g). (d) Relative serum concentration of inflammatory cytokines in the 
serum of Kras;p53 mutant mice treated with vehicle control or JQ1 (n = 3 for each 
experimental group) and wild-type (WT) animals, (e) Quantitative RT-PCR analysis of IL6 
and IL1a mRNA expression in patient-derived PDAC xenografts following treatment with 
JQ1 or vehicle control (see Fig. 4e) (six biological replicates for each experimental 
condition). **P < 0.01; ***P < 0.001 (two-tailed unpaired Student’s t-test). Data are 
represented as mean ± s.e.m. (f) Effects of BRD4 inhibition via shRNA or JQ1 treatment on 
IL6 levels in the conditioned medium of human PDAC CFPac1 cells and for MYC and 
STAT3 as assessed by immunoblot. **P < 0.01; ***P < 0.001; n.s., not significant (two-
tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m. (g) Schematic 
representation of the human IL6 promoter (UCSC Gene Browser) with integrated epigenetic 
regulation marks and RNA polymerase II binding (POL2RA, green bar) (ENCODE). 
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Localization of primers used for chromatin immunoprecipitation analysis is indicated by A–
F. (h) Chromatin immunoprecipitation analysis of BRD4 at the IL6 promoter in CFPac1 
cells treated with vehicle control (−) or JQ1 (+). The data are plotted relative to the values 
obtained with IgG control antibodies. **P < 0.01; ***P < 0.001 (two-tailed unpaired 
Student’s t-test). Data are represented as mean ± s.e.m. (i) Schematic of the caerulein 
pancreatitis– induced preneoplastic (PanIN) lesion formation protocol for the rescue 
experiment with exogenous IL6 injection upon JQ1 treatment. (j) Top, representative 
pancreata images (of n = 5 each, scale bars, 1 cm) and HE staining (scale bars, 100 µm) in 
Kras mutant mice in the four experimental conditions indicated (IHC and immunoblot 
biopsy analysis shown in Supplementary Fig. 7a,b). Bottom, quantification of MUC5AC-
positive lesions in caerulein-treated pancreata from each experimental group (the control 
group was injected with vehicle control) (n = 5 each; IHC staining on Supplementary Fig. 
7a). ***P < 0.001; n.s., not significant (two-tailed unpaired Student’s t-test). Data are 
represented as mean ± s.e.m.
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Figure 3. 
Synergistic inhibitory effects of JQ1 and the HDAC inhibitor SAHA in PDAC. (a) 
Combination index (CI) calculation for JQ1 and SAHA. CFPac1 cell viability was measured 
after 72 h of drug treatment by the MTT survival assay. (b) Validation of the synergistic 
inhibitory effects of combined treatment with JQ1 and SAHA as measured by the MTT 
assay in human DanG PDAC cells after 72 h of treatment. Data are represented as mean ± 
s.e.m. (c) Quantification of apoptotic cell death by annexin V staining in DanG cells 
following treatment with JQ1 and SAHA (n = 3 independent replicates). ***P < 0.001 (two-
tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m. (d) Immunoblot 
analysis of BRD4, MYC and apoptosis markers in DanG cells treated with JQ1 and SAHA. 
β-actin served as a loading control. (e) Representative pictures of colony-formation assays 
with DanG cells in response to JQ1 and SAHA treatment, with quantification at right (n = 3 
for each experimental group). ***P < 0.001; n.s., not significant (two-tailed unpaired 
Student’s t-test). Data are represented as mean ± s.e.m. The control group was treated with 
vehicle control (b,c–e). (f) Schematic of the caerulein pancreatitis–induced preneoplastic 
(PanIN) lesion formation protocol in Kras mutant mice for JQ1 and SAHA co-treatment or 
control (vehicle) experiment. (g) Representative pancreata images (from n = 5 for each 
experimental group). Scale bars, 1 cm. (h) Quantification of MUC5AC-positive lesions in 
caerulein-treated Kras mutant mice pancreata from each experimental group (n = 5 for each 
experimental group; IHC staining in Supplementary Fig. 9a,b). ***P < 0.001; n.s., not 
significant (two-tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m.
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Figure 4. 
Combined treatment with JQ1 and SAHA inhibits PDAC progression in vivo. (a) Treatment 
schedule for administration of JQ1 and SAHA. Kras;p53 mutant mice undergoing 
monotherapy also received placebo (vehicle) (IHC and immunoblot biopsy analysis in 
Supplementary Fig. 11a–f). (b) Kaplan-Meier survival curves of Kras;p53 mutant mice from 
enrollment time in control (vehicle) (n = 9, median survival = 15 d), SAHA (n = 9, median 
survival = 16 d), JQ1 (n = 9 median survival = 24 d, as in Fig. 1j) and combined JQ1 + 
SAHA (n = 10, median survival = 47 d) treatment groups. *P < 0.05; ***P < 0.001; n.s., not 
significant by log-rank test for significance. (c) Representative MRI scan showing 
measurement of tumor size in Kras;p53 mutant mice at time of animal morbidity. Red dotted 
lines indicate tumor area. Scale bars, 1 cm. (d) Tumor volume quantification based on MRI 
scan of Kras;p53 mutant mice in the treatment groups: control (vehicle), n = 9; SAHA, n = 
9; JQ1, n = 5; JQ1 + SAHA, n = 5. *P < 0.05; ***P < 0.001; n.s., not significant (two-tailed 
unpaired Student’s t-test). Data are represented as mean ± s.e.m. (e) Treatment schedule for 
administration of JQ1 and SAHA in a PDX model. (f) Representative macroscopic picture of 
xenografts from control (vehicle), SAHA, JQ1 and combined JQ1 + SAHA treatment groups 
at the end of the experiment. Scale bar, 1 cm. (g) Tumor volume quantification of patient-
derived PDAC xenografts in mice (n = 4 mice, two tumors per mouse for each treatment 
group). Mice undergoing monotherapy also received vehicle. ***P < 0.001; n.s., not 
significant (two-tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m.
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Figure 5. 
JQ1 and SAHA synergistically suppress lung adenocarcinoma growth in vivo. (a) Treatment 
schedule for administration of JQ1 and SAHA. Kras;p53 mutant mice undergoing 
monotherapy also received placebo (vehicle). (b) Kaplan-Meier survival curves of Kras;p53 
mutant mice from enrollment time in control (vehicle) (n = 6, median survival = 87.5 d), 
SAHA (n = 6, median survival = 92.5 d), JQ1 (n = 6 med. survival = 109.5 d) and combined 
SAHA + JQ1 (n = 6, median survival = 138.5 d) treatment groups. *P < 0.05; **P < 0.01; 
n.s., not significant by log-rank test for significance. (c) Quantification of tumor area per 
lung area. ***P < 0.001; n.s., not significant (two-tailed unpaired Student’s t-test). Data are 
represented as mean ± s.e.m. (d) Treatment schedule for administration of JQ1 and SAHA in 
a lung adenocarcinoma patient-derived xenograft. (e) Tumor volume quantification for lung 
adenocarcinoma xenografts in mice (n = 5 mice for each treatment group and vehicle 
control). ***P < 0.001 (two-tailed unpaired Student’s t-test). Data are represented as mean ± 
s.e.m.
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Figure 6. 
Identification of p57 as a key mediator of PDAC sensitivity to JQ1 and SAHA co-treatment 
using a gene editing platform in the pancreas of mice. (a) Immunoblot analysis of pancreatic 
tumor lysates dissected from Kras;p53 mutant mice in response to the indicated treatments 
and vehicle control (multiple independent mouse tumors were obtained and analyzed; two 
independent and representative samples are shown). (b) Immunoblot analysis of a patient-
derived PDAC xenograft in response to the indicated treatments. (c) Immunoblot analysis of 
the human PDAC cell line CFPac1 following p57 knockdown (shp57) or scrambled shRNA 
(shControl) in response to JQ1 (250 nM) and SAHA (250 nM) treatment for 72 h. (d) 
Chromatin immunoprecipitation analysis of acetylated histone H3 (H3Ac) at the p57 
promoter in JQ1 (250 nM) and SAHA (250 nM) or vehicle control–treated CFPac1 cells. *P 
< 0.05 (two-tailed unpaired Student’s t-test). Data are represented as mean ± s.e.m. of two 
independent experiments. (e) sgRNA design for targeting the mouse p57 locus. (f) Top, map 
of the pSECC lentivirus for the simultaneous expression of sgRNA, Cas9 and Cre, which 
allows genome editing and gene recombination when injected into the pancreatic 
parenchyma. Bottom, schematic of experimental caerulein- and lentiviral pSECC-induced 
tumorigenesis in Kras+/LSL-G12D;Trp53loxP/loxP mice with JQ1 and SAHA co-treatment. (g) 
Representative fluorescence (right, tdTomato) and bright-field (left) images of pancreatic 
tumors in Kras+/LSL-G12D;Trp53loxP/loxP;R26tdTomato mice following pSECC injection. (h) 
Surveyor assay for p57 on tumor biopsies from mice infected with pSECC viruses 
expressing sgControl or sgp57 guide RNAs. T, tumor, each number represents different 
mouse tumor biopsies. (i) Left, representative HE and IHC analysis (p57, cleaved caspase 3) 
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from pancreatic tumors sections in Kras+/LSL-G12D;p53loxP/loxP mice infected with pSECC 
sgControl and shp57 lentiviruses and co-treated with JQ1 and SAHA or vehicle control (see 
also Supplementary Fig. 15d). Scale bars, 100 µm, insets 50 µm. Right, quantification of 
cleaved caspase 3–positive cells on tumor sections from control and treated mice (n = 4 for 
each experimental group). **P < 0.01; n.s., not significant (two-tailed unpaired Student’s t-
test). Data are represented as mean ± s.e.m. (j) A proposed model for synergistic JQ1 and 
SAHA co-treatment of PDAC. Inhibition of MYC and inflammatory signals by the inhibitor 
of BET family proteins JQ1 and inhibition of HDAC activity by SAHA affects several key 
signaling cascades in PDAC cells. JQ1 and SAHA co-treatment alters the expression of 
multiple gene programs, including that of p57, which results in a strong antitumoral 
response.
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